# Daniel J. Wallace

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-j-wallace/

## Facts

| Field | Value |
| --- | --- |
| Citations | 42,859 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 94 |
| i10-index | 310 |
| OpenAlex ID | https://openalex.org/A5071430304 |
| ORCID iD | 0000-0002-2502-1372 |
| Works | 782 |

## Researcher papers

Showing 12 of 21.

- [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/derivation-and-validation-of-the-systemic-lupus-international-collaborating/)
- [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/)
- [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](https://scholariq.org/papers/a-phase-iii-randomized-placebo-controlled-study-of-belimumab-a-monoclonal/)
- [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology-2/)
- [American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis](https://scholariq.org/papers/american-college-of-rheumatology-guidelines-for-screening-treatment-and/)
- [Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial](https://scholariq.org/papers/efficacy-and-safety-of-rituximab-in-moderately-to-severely-active-systemic-lupus/)
- [Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis](https://scholariq.org/papers/mycophenolate-mofetil-or-intravenous-cyclophosphamide-for-lupus-nephritis/)
- [Dubois' Lupus Erythematosus](https://scholariq.org/papers/dubois-lupus-erythematosus/)
- [Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)](https://scholariq.org/papers/sustained-benefits-of-infliximab-therapy-for-dermatologic-and-articular/)
- [The frequency and outcome of lupus nephritis: results from an international inception cohort study](https://scholariq.org/papers/the-frequency-and-outcome-of-lupus-nephritis-results-from-an-international/)
- [A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis](https://scholariq.org/papers/a-short-course-of-bg9588-anti-cd40-ligand-antibody-improves-serologic-activity/)
- [A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus](https://scholariq.org/papers/a-phase-ii-randomized-double-blind-placebo-controlled-dose-ranging-study-of/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Fibromyalgia and Chronic Fatigue Syndrome Research](https://scholariq.org/topics/fibromyalgia-and-chronic-fatigue-syndrome-research/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.